Manuel Lucy, Fong Laura S, Wolfenden Hugh, Bassin Levi
Department of Cardiothoracic Surgery, Royal North Shore Hospital, Sydney, Australia.
Department of Cardiothoracic Surgery, Prince of Wales Hospital, Sydney, Australia.
Ann Med Surg (Lond). 2020 Aug 11;57:264-267. doi: 10.1016/j.amsu.2020.07.060. eCollection 2020 Sep.
A best evidence topic in cardiac surgery was written according to a structured protocol. The question addressed was 'Is totally endoscopic coronary artery bypass grafting compared with minimally invasive direct coronary artery bypass grafting associated with superior outcomes in patients with isolated left anterior descending disease?' Altogether more than 118 papers were found using the reported search, of which 4 represented the best evidence to answer the clinical question, which included 2 prospective cohort studies and 2 retrospective observational studies. The authors, journal, date and country of publication, patient group studied, study type, relevant outcomes and results of these papers were tabulated. There is a significant variation within the MIDCAB and TECAB techniques amongst the studies-including the experience of the surgeon, use of cardiopulmonary bypass, patient selection, and target vessel grafting strategies-highlighting the complexity of comparing these two minimally invasive procedures. Operative times were comparable across all studies, with TECAB patients having higher transfusions rates and conversion rates to either a median sternotomy or MIDCAB procedure. Overall safety was comparable between the two cohort groups, with similar length of stay and 30-day mortality. However, the TECAB group were more likely to require re-operation for bleeding and reintervention for early revascularisation with greater total hospital costs than the MIDCAB patients. Based on the available evidence, we conclude that TECAB is associated with a higher rate of transfusions, conversion to median sternotomy or MIDCAB, early graft failure and reintervention compared to the MIDCAB approach. We advise caution in adopting a TECAB approach.
根据结构化方案撰写了一篇心脏外科的最佳证据主题。所探讨的问题是“对于单纯左前降支病变患者,完全内镜冠状动脉旁路移植术与微创直接冠状动脉旁路移植术相比,是否能带来更好的治疗效果?”通过报告的检索共找到118多篇论文,其中4篇代表了回答该临床问题的最佳证据,包括2项前瞻性队列研究和2项回顾性观察研究。将这些论文的作者、期刊、发表日期和国家、研究的患者组、研究类型、相关结局和结果制成表格。在各研究中,微创直接冠状动脉旁路移植术(MIDCAB)和完全内镜冠状动脉旁路移植术(TECAB)技术存在显著差异,包括外科医生的经验、体外循环的使用、患者选择以及目标血管移植策略等,这凸显了比较这两种微创手术的复杂性。所有研究中的手术时间相当,TECAB患者的输血率和转为正中开胸或MIDCAB手术的转化率更高。两个队列组的总体安全性相当,住院时间和30天死亡率相似。然而,与MIDCAB患者相比,TECAB组因出血需要再次手术以及因早期血运重建需要再次干预的可能性更大,总住院费用更高。基于现有证据,我们得出结论,与MIDCAB方法相比,TECAB的输血率、转为正中开胸或MIDCAB的转化率、早期移植失败和再次干预的发生率更高。我们建议在采用TECAB方法时谨慎行事。